In a report released today, Tara Bancroft from TD Cowen maintained a Buy rating on Mersana Therapeutics (MRSN – Research Report). The company’s shares closed last Friday at $0.75. Leverage the ...

Anna Commander is a Newsweek Editor and writer based in Florida. Her focus is reporting on crime, weather and breaking news. She has covered weather, and major breaking news events in South Florida.

Anna Skinner is a Newsweek senior reporter based in Indianapolis. Her focus is reporting on the climate, environment and weather but she also reports on other topics for the National News Team.

Mersana’s lead product candidate, upifitamab rilsodotin (UpRi), is a Dolaflexin ADC targeting NaPi2b that is being studied in UPLIFT, a single-arm registrational trial in patients with ...

Pre-Market: 5:02:04 a.m. EST Loading Chart for MRSN ...

The biggest stories of the day delivered to your inbox.

After hours: February 10 at 5:00:28 PM EST Loading Chart for GDTC ...

Dyne Therapeutics Inc.-5.60% $1.56B ...